Company / Operating Cash Flow per Share
Edgewise Therapeutics, Inc. Operating Cash Flow per Share History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow per Share
-$1.40
FY2025
5-year range
-$1.44 / -$0.89
FY2021-FY2025
Trend
-18.4%
vs FY2024
Sector context
#130 of 212
Health Care
What the data says
At $-1.40, Edgewise Therapeutics, Inc.'s operating cash flow per share ranks #130 of 212 in the Health Care sector. Operating Cash Flow per Share has fluctuated over the past 6 years, ranging from $-19.80 in FY2020 to $-0.89 in FY2021.
Based on SEC 10-K filings.
-1.40 in FY2025.
Improved from $-1.44 to $-1.40 over the past 2 years.
Health Care sector context is included.
Operating Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#130 of 212 in Health CareTop 61% of 212This company -$1.40 Sector average $5.28
▼
-126.5% below sector average
Key checks
Key Insights
- In FY2025, operating cash flow per share decreased 18.4% year-over-year.
- Ranks #130 out of 212 companies in the Health Care sector.
- Peak operating cash flow per share was recorded in FY2021.
- Lowest operating cash flow per share in the period was in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 6.82 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$1.40 | -18.4% |
| FY2024 | -$1.18 | +18.2% |
| FY2023 | -$1.44 | -46.9% |
| FY2022 | -$0.98 | -10.0% |
| FY2021 | -$0.89 | +95.5% |
| FY2020 | -$19.80 | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026